| Dr Kuldip Jbs Behniwal, MD | |
|
7014 N Whitney Ave, Ste A, Fresno, CA 93720-0155 | |
| (559) 321-2858 | |
| (559) 321-2780 |
| Full Name | Dr Kuldip Jbs Behniwal |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 50 Years |
| Location | 7014 N Whitney Ave, Fresno, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356346365 | NPI | - | NPPES |
| 00A395860 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | A395860 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Clovis Community Medical Center | Clovis, CA | Hospital |
| Community Regional Medical Center | Fresno, CA | Hospital |
| Saint Agnes Medical Center | Fresno, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Urology Associates Of Central California Medical Group Inc | 8820068489 | 11 |
News Archive
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.
A £1.1 million grant to understand how one of the brain's key neurotransmitters called 'acetylcholine' influences brain activity has been awarded to University of Bristol researchers. The Wellcome Trust award will help scientists understand more precisely how the release of acetylcholine is changing brain cell activity to influence memory and cognition.
A sophisticated type of artificial intelligence can detect clinically meaningful chest X-ray findings as effectively as experienced radiologists, according to a study published in the journal Radiology.
A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.
St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) clearance, CE Mark approval and the launch of the EnSite Derexi™ module, which provides improved electrophysiology (EP) lab efficiency and workflow by enabling communication between the EnSite™ Velocity™ Cardiac Mapping System and the EP-Workmate™ Recording System.
› Verified 5 days ago
| Entity Name | Urology Associates Of Central California Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194720722 PECOS PAC ID: 8820068489 Enrollment ID: O20040729001415 |
News Archive
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.
A £1.1 million grant to understand how one of the brain's key neurotransmitters called 'acetylcholine' influences brain activity has been awarded to University of Bristol researchers. The Wellcome Trust award will help scientists understand more precisely how the release of acetylcholine is changing brain cell activity to influence memory and cognition.
A sophisticated type of artificial intelligence can detect clinically meaningful chest X-ray findings as effectively as experienced radiologists, according to a study published in the journal Radiology.
A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.
St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) clearance, CE Mark approval and the launch of the EnSite Derexi™ module, which provides improved electrophysiology (EP) lab efficiency and workflow by enabling communication between the EnSite™ Velocity™ Cardiac Mapping System and the EP-Workmate™ Recording System.
› Verified 5 days ago
| Entity Name | Urology Associates Of Central California, Inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1194720730 PECOS PAC ID: 0345288023 Enrollment ID: O20050422000337 |
News Archive
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.
A £1.1 million grant to understand how one of the brain's key neurotransmitters called 'acetylcholine' influences brain activity has been awarded to University of Bristol researchers. The Wellcome Trust award will help scientists understand more precisely how the release of acetylcholine is changing brain cell activity to influence memory and cognition.
A sophisticated type of artificial intelligence can detect clinically meaningful chest X-ray findings as effectively as experienced radiologists, according to a study published in the journal Radiology.
A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.
St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) clearance, CE Mark approval and the launch of the EnSite Derexi™ module, which provides improved electrophysiology (EP) lab efficiency and workflow by enabling communication between the EnSite™ Velocity™ Cardiac Mapping System and the EP-Workmate™ Recording System.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kuldip Jbs Behniwal, MD 7014 N Whitney Ave, Ste A, Fresno, CA 93720-0155 Ph: (559) 321-2858 | Dr Kuldip Jbs Behniwal, MD 7014 N Whitney Ave, Ste A, Fresno, CA 93720-0155 Ph: (559) 321-2858 |
News Archive
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.
A £1.1 million grant to understand how one of the brain's key neurotransmitters called 'acetylcholine' influences brain activity has been awarded to University of Bristol researchers. The Wellcome Trust award will help scientists understand more precisely how the release of acetylcholine is changing brain cell activity to influence memory and cognition.
A sophisticated type of artificial intelligence can detect clinically meaningful chest X-ray findings as effectively as experienced radiologists, according to a study published in the journal Radiology.
A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.
St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) clearance, CE Mark approval and the launch of the EnSite Derexi™ module, which provides improved electrophysiology (EP) lab efficiency and workflow by enabling communication between the EnSite™ Velocity™ Cardiac Mapping System and the EP-Workmate™ Recording System.
› Verified 5 days ago
Alice K Tsao, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 7300 N Fresno St, Oak 2, Fresno, CA 93720 Phone: 559-448-4407 | |
Berhane Mebratu, NP Urology Medicare: Medicare Enrolled Practice Location: 7014 N Whitney Ave, Fresno, CA 93720 Phone: 559-321-2800 Fax: 559-321-2780 | |
Dr. Yuk-yuen Max Leung, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 7014 N Whitney Ave, Ste A, Fresno, CA 93720 Phone: 559-321-2800 Fax: 559-321-2780 | |
Dr. Narayana Sriman Ambati, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 7014 N Whitney Ave, Ste A, Fresno, CA 93720 Phone: 559-321-2858 Fax: 559-321-2780 | |
Dr. Artin Y Jibilian, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 255 N. Howard, Fresno, CA 93701 Phone: 559-459-7300 Fax: 559-459-3750 | |
Dr. Nedra Yvonne Hood, MD Urology Medicare: Medicare Enrolled Practice Location: 7300 N Fresno St, Fresno, CA 93720 Phone: 559-448-4900 |